Nuvation Bio (NUVB) Equity Average: 2020-2025

Nuvation Bio's Equity Average fell 6.92% to $396.2 million in Q2 2025 from the same period last year, while for Jun 2025 it was $396.2 million, marking a year-over-year decrease of 6.92%. This contributed to the annual value of $534.5 million for FY2024, which is 15.18% down from last year.
Per Nuvation Bio's latest filing, its Equity Average stood at $396.2 million for Q2 2025, which was up 4.27% from $380.0 million recorded in Q3 2024.
Nuvation Bio's Equity Average's 5-year high stood at $797.6 million during Q2 2021, with a 5-year trough of $380.0 million in Q3 2024.
Moreover, its 3-year median value for Equity Average was $425.6 million (2024), whereas its average is $490.5 million.
As far as peak fluctuations go, Nuvation Bio's Equity Average soared by 30,917.13% in 2021, and later crashed by 38.53% in 2024.
Quarterly analysis of 5 years shows Nuvation Bio's Equity Average stood at $779.2 million in 2021, then decreased by 12.66% to $680.5 million in 2022, then fell by 9.17% to $618.1 million in 2023, then slumped by 38.53% to $380.0 million in 2024, then fell by 6.92% to $396.2 million in 2025.
Its Equity Average was $396.2 million in Q2 2025, compared to $380.0 million in Q3 2024 and $425.6 million in Q2 2024.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Equity Avg. (Qtr)
1	Summit Therapeutics Inc.	1,387.71B	1,387.50B	-	301.88M
2	BeOne Medicines Ltd.	458.68B	457.16B	1.15B	3.63B
3	Vertex Pharmaceuticals Inc / Ma	102.37B	99.35B	-	16.84B
4	Benitec Biopharma Inc.	65.38B	65.31B	-	86.76M
5	Regeneron Pharmaceuticals, Inc.	60.67B	60.28B	-	29.66B
6	Alnylam Pharmaceuticals, Inc.	60.53B	62.66B	-	183.01M
7	Argenx Se	45.96B	50.00B	-	-
8	INSMED Inc	26.50B	27.40B	-	674.45M
9	BioNTech SE	25.15B	17.24B	-	-
10	Nuvation Bio Inc.	1.42B	1.38B	2.26M	396.18M